Tumor growth and metastases in malignant disease. A review
- PMID: 3141546
Tumor growth and metastases in malignant disease. A review
Abstract
Various human malignant tumors, including malignant melanoma, showed an absence of fibrinolytic activity by the histochemical fibrin slide method. In contrast, a tissue plasminogen activator has been isolated both from extracts of melanoma tissues and melanoma cell lines in culture, and has been characterized to be a potent plasminogen activator. In an attempt to resolve this apparent discrepancy, we studied biopsied specimens of melanoma and several melanoma cell lines by the immunoperoxidase method. Tissue plasminogen activator was observed in melanoma tissues and cell lines while the various inhibitors of fibrinolysis, including alpha 2-anti-plasmin, alpha 2-macroglobulin, alpha 1-antitrypsin, and antithrombin III were found intracellularly only in the melanoma tumor cells, but not in melanoma cell lines. We believe that these inhibitors are derived from the blood and are bound to the tissue plasminogen activator within the melanoma cells. This hypothesis is supported by in vivo studies showing binding of tissue plasminogen activator in cultured cell lines to several inhibitors. Since these are potent inhibitors of fibrinolysis, their presence in tumor cells would explain the lack of fibrinolytic activity in melanoma tissues.
Similar articles
-
Tissue plasminogen activator and inhibitors of fibrinolysis in malignant melanoma.Tumour Biol. 1988;9(6):301-6. doi: 10.1159/000217576. Tumour Biol. 1988. PMID: 3144730
-
Fibrinolysis activity promotes tumor invasiveness of B16 melanoma cell lines through a reconstituted gel matrix.Invasion Metastasis. 1992;12(1):24-34. Invasion Metastasis. 1992. PMID: 1380952
-
Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.J Clin Invest. 1995 May;95(5):2096-103. doi: 10.1172/JCI117897. J Clin Invest. 1995. PMID: 7537755 Free PMC article.
-
Binding of tissue-type plasminogen activator to human melanoma cells.J Cell Biochem. 1993 Mar;51(3):326-35. doi: 10.1002/jcb.240510312. J Cell Biochem. 1993. PMID: 8501135
-
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.Dan Med Bull. 1993 Sep;40(4):383-408. Dan Med Bull. 1993. PMID: 8222763 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical